{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:52:26Z","timestamp":1783702346271,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Diffuse large B\u2010cell lymphoma (DLBCL) is the most common B\u2010cell non\u2010Hodgkin lymphoma in the world. Treatment options for relapsed DLBCL in the third line and beyond include chimeric antigen receptor T\u2010cell therapy, T\u2010cell\u2013engaging bispecific antibodies, and loncastuximab tesirine (loncastuximab tesirine\u2010lpyl [Lonca]), each with unique toxicity profiles. There is still an unmet need for guidance on managing Lonca\u2010associated adverse events (AEs), particularly for oncologists who have limited experience with this antibody\u2013drug conjugate. Here, an online survey among lymphoma specialists in the US between June and August 2024 assessed practice patterns and experiences, including Lonca treatment patterns, AE management, patient concerns, and physician perceptions. Based on these responses, an algorithm was developed to help manage Lonca\u2010associated AEs. The most commonly reported AEs were edema and rash\/photosensitivity, typically occurring within the first 4 doses, whereas fatigue was the most common patient concern. Lonca\u2010associated AEs were managed by delaying or discontinuing Lonca or by prescribing diuretics, steroids, or antihistamines, depending on the AE observed. The survey results align with findings from prior clinical trials and support the manageability of Lonca\u2010associated AEs in a wide variety of settings. The included algorithm provides guidance for managing AEs, such as edema, myelosuppression, and cutaneous reactions.<\/jats:p>","DOI":"10.1002\/hon.70128","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T03:49:53Z","timestamp":1755748193000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B\u2010Cell Lymphoma"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies Huntsman Cancer Institute University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Brown University Health  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Ayers","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Virginia Health System  Charlottesville Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma and Stem Cell Transplantation &amp; Cellular Therapy UT MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.738693"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010005"},{"key":"e_1_2_12_4_1","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for B\u2010Cell Lymphomas V.2.2025","author":"National Comprehensive Cancer Network","year":"2025","journal-title":"National Comprehensive Cancer Network"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2027612"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa011795"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.05.1003"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2115304"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201003\u2010276246"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116133"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(20)30120\u20104"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00139\u2010x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010151583"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)31366\u20100"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01725"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206913"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(20)30225\u20104"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001084\u2010w"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013289"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014663"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201010\u2010813493"},{"key":"e_1_2_12_24_1","volume-title":"ZYNLONTA. Loncastuximab tesirine\u2010lpyl","author":"US Food and Drug Administration","year":"2022"},{"key":"e_1_2_12_25_1","unstructured":"US Food and Drug Administration.Drugs@Fda: Fda\u2010Approved Drugs accessed April 8 2025 https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=761196."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283459"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001195\u20104"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285977"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201000997\u2010w"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3154"},{"key":"e_1_2_12_31_1","unstructured":"H.MistryandS.Ahmed 2022. \u201cCase Study: Photosensitivity Rash Associated With Loncastuximab Teserine. Presented At: Pan Pacific Lymphoma Conference.\u201d"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.08.013"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:51:53Z","timestamp":1759549913000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/hon.70128"],"URL":"https:\/\/doi.org\/10.1002\/hon.70128","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"2025-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70128"}}